Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Kidney Failure, Chronic | 121 | 2024 | 231 | 20.780 |
Why?
|
Renal Insufficiency, Chronic | 55 | 2023 | 160 | 15.880 |
Why?
|
Renal Dialysis | 68 | 2024 | 119 | 12.720 |
Why?
|
Kidney Diseases | 48 | 2023 | 159 | 10.650 |
Why?
|
Hypertension | 59 | 2022 | 770 | 7.220 |
Why?
|
Humans | 389 | 2024 | 34853 | 5.270 |
Why?
|
Healthcare Disparities | 22 | 2024 | 446 | 5.240 |
Why?
|
United States | 138 | 2024 | 3894 | 5.230 |
Why?
|
Glomerular Filtration Rate | 48 | 2023 | 137 | 5.200 |
Why?
|
Cardiovascular Diseases | 27 | 2022 | 628 | 4.800 |
Why?
|
Vitamin D | 17 | 2020 | 176 | 3.980 |
Why?
|
Vitamin D Deficiency | 13 | 2022 | 94 | 3.700 |
Why?
|
Biomedical Research | 14 | 2021 | 371 | 3.650 |
Why?
|
Minority Groups | 24 | 2023 | 537 | 3.520 |
Why?
|
Health Services Accessibility | 17 | 2023 | 531 | 3.370 |
Why?
|
Community-Institutional Relations | 16 | 2022 | 171 | 3.280 |
Why?
|
Middle Aged | 155 | 2024 | 9642 | 3.250 |
Why?
|
Diabetic Nephropathies | 16 | 2023 | 53 | 3.250 |
Why?
|
Community-Based Participatory Research | 16 | 2022 | 292 | 3.230 |
Why?
|
Health Status Disparities | 23 | 2023 | 583 | 3.110 |
Why?
|
Male | 200 | 2024 | 18870 | 3.090 |
Why?
|
Renal Insufficiency | 6 | 2023 | 18 | 3.010 |
Why?
|
Aged | 126 | 2023 | 6448 | 3.000 |
Why?
|
Kidney Transplantation | 12 | 2022 | 85 | 2.990 |
Why?
|
Female | 187 | 2024 | 19873 | 2.820 |
Why?
|
Risk Factors | 74 | 2023 | 3414 | 2.780 |
Why?
|
Kidney | 22 | 2024 | 322 | 2.760 |
Why?
|
Antihypertensive Agents | 18 | 2019 | 284 | 2.740 |
Why?
|
Poverty | 11 | 2023 | 316 | 2.700 |
Why?
|
Nephrology | 12 | 2022 | 17 | 2.620 |
Why?
|
Universities | 13 | 2022 | 363 | 2.610 |
Why?
|
Cooperative Behavior | 18 | 2015 | 205 | 2.430 |
Why?
|
Blood Pressure | 23 | 2022 | 613 | 2.420 |
Why?
|
Albuminuria | 15 | 2022 | 76 | 2.410 |
Why?
|
Diabetes Mellitus, Type 2 | 14 | 2023 | 592 | 2.400 |
Why?
|
Adult | 122 | 2023 | 11034 | 2.390 |
Why?
|
Creatinine | 20 | 2023 | 101 | 2.380 |
Why?
|
Diabetes Mellitus | 15 | 2023 | 465 | 2.010 |
Why?
|
Mass Screening | 20 | 2013 | 427 | 1.970 |
Why?
|
Public Policy | 2 | 2023 | 31 | 1.890 |
Why?
|
Obesity | 17 | 2022 | 965 | 1.880 |
Why?
|
Cultural Diversity | 4 | 2023 | 158 | 1.780 |
Why?
|
Oxidative Stress | 10 | 2018 | 874 | 1.620 |
Why?
|
Electronic Health Records | 3 | 2021 | 65 | 1.580 |
Why?
|
Nutrition Surveys | 21 | 2022 | 228 | 1.580 |
Why?
|
Vulnerable Populations | 9 | 2015 | 132 | 1.540 |
Why?
|
Research Design | 13 | 2023 | 292 | 1.530 |
Why?
|
Endocarditis | 2 | 2020 | 11 | 1.510 |
Why?
|
Cohort Studies | 33 | 2023 | 1422 | 1.500 |
Why?
|
Faculty | 4 | 2023 | 82 | 1.470 |
Why?
|
Aged, 80 and over | 34 | 2023 | 2333 | 1.460 |
Why?
|
Coronary Disease | 7 | 2016 | 113 | 1.440 |
Why?
|
Disease Progression | 25 | 2022 | 580 | 1.400 |
Why?
|
Population Surveillance | 5 | 2018 | 231 | 1.390 |
Why?
|
Hypertension, Renal | 8 | 2010 | 15 | 1.380 |
Why?
|
Insurance, Health | 5 | 2016 | 120 | 1.370 |
Why?
|
Prevalence | 29 | 2021 | 1425 | 1.370 |
Why?
|
Health Promotion | 13 | 2022 | 588 | 1.360 |
Why?
|
Health Services Research | 9 | 2015 | 133 | 1.360 |
Why?
|
Veterans | 6 | 2023 | 115 | 1.340 |
Why?
|
Prospective Payment System | 2 | 2019 | 6 | 1.290 |
Why?
|
Risk Assessment | 22 | 2021 | 727 | 1.280 |
Why?
|
Community Networks | 3 | 2018 | 98 | 1.260 |
Why?
|
Allostasis | 3 | 2022 | 10 | 1.260 |
Why?
|
Adolescent | 52 | 2023 | 5035 | 1.250 |
Why?
|
Chronic Disease | 28 | 2016 | 469 | 1.250 |
Why?
|
Public Health | 8 | 2021 | 348 | 1.240 |
Why?
|
Religion | 5 | 2022 | 77 | 1.220 |
Why?
|
Registries | 9 | 2023 | 330 | 1.220 |
Why?
|
Cystine | 3 | 2013 | 12 | 1.210 |
Why?
|
Los Angeles | 26 | 2022 | 368 | 1.210 |
Why?
|
Proportional Hazards Models | 22 | 2021 | 423 | 1.170 |
Why?
|
Empathy | 2 | 2018 | 26 | 1.130 |
Why?
|
Program Evaluation | 10 | 2018 | 316 | 1.130 |
Why?
|
Malnutrition | 4 | 2020 | 45 | 1.120 |
Why?
|
Acetylcysteine | 3 | 2011 | 58 | 1.110 |
Why?
|
Body Mass Index | 10 | 2021 | 775 | 1.100 |
Why?
|
Waiting Lists | 4 | 2017 | 33 | 1.090 |
Why?
|
Medicine | 3 | 2023 | 31 | 1.090 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2018 | 77 | 1.070 |
Why?
|
Treatment Outcome | 21 | 2023 | 1349 | 1.060 |
Why?
|
Cystatin C | 2 | 2022 | 21 | 1.060 |
Why?
|
Government Regulation | 2 | 2024 | 15 | 1.050 |
Why?
|
Research | 8 | 2020 | 159 | 1.050 |
Why?
|
Hypertrophy, Left Ventricular | 5 | 2019 | 46 | 1.040 |
Why?
|
Stress, Psychological | 3 | 2020 | 541 | 1.040 |
Why?
|
Heart Failure | 4 | 2022 | 230 | 1.040 |
Why?
|
Mentors | 4 | 2023 | 111 | 1.030 |
Why?
|
Medicare | 6 | 2023 | 188 | 1.030 |
Why?
|
Residence Characteristics | 2 | 2019 | 301 | 1.030 |
Why?
|
Patient Education as Topic | 4 | 2019 | 207 | 1.020 |
Why?
|
Inflammation | 14 | 2018 | 577 | 1.010 |
Why?
|
Hypoglycemic Agents | 4 | 2021 | 152 | 1.000 |
Why?
|
Socioeconomic Factors | 17 | 2019 | 1003 | 0.980 |
Why?
|
Information Dissemination | 5 | 2015 | 58 | 0.970 |
Why?
|
Hospitalization | 9 | 2023 | 370 | 0.970 |
Why?
|
Health Facilities | 1 | 2023 | 23 | 0.960 |
Why?
|
Health Education | 7 | 2016 | 304 | 0.960 |
Why?
|
Patient Participation | 4 | 2023 | 68 | 0.930 |
Why?
|
Parathyroid Hormone | 17 | 2022 | 36 | 0.920 |
Why?
|
Program Development | 14 | 2016 | 225 | 0.920 |
Why?
|
Health Occupations | 4 | 2008 | 15 | 0.920 |
Why?
|
Retrospective Studies | 17 | 2023 | 1961 | 0.920 |
Why?
|
Family Health | 4 | 2010 | 47 | 0.900 |
Why?
|
Vitamins | 5 | 2022 | 91 | 0.900 |
Why?
|
National Institutes of Health (U.S.) | 6 | 2020 | 77 | 0.880 |
Why?
|
Age Factors | 18 | 2017 | 1007 | 0.880 |
Why?
|
Cross-Sectional Studies | 30 | 2024 | 2561 | 0.860 |
Why?
|
Students | 6 | 2020 | 452 | 0.860 |
Why?
|
Public-Private Sector Partnerships | 4 | 2010 | 12 | 0.860 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 13 | 2023 | 64 | 0.850 |
Why?
|
Cholesterol | 6 | 2013 | 194 | 0.840 |
Why?
|
Cholecalciferol | 3 | 2022 | 19 | 0.840 |
Why?
|
Medicare Part C | 1 | 2021 | 12 | 0.840 |
Why?
|
Young Adult | 27 | 2022 | 4012 | 0.830 |
Why?
|
Heart Diseases | 1 | 2022 | 99 | 0.820 |
Why?
|
Incidence | 18 | 2022 | 882 | 0.800 |
Why?
|
Mortality | 4 | 2022 | 150 | 0.800 |
Why?
|
Calcitriol | 7 | 2015 | 30 | 0.790 |
Why?
|
Prediabetic State | 4 | 2023 | 51 | 0.780 |
Why?
|
Stroke | 5 | 2016 | 274 | 0.770 |
Why?
|
Medical Record Linkage | 2 | 2019 | 15 | 0.770 |
Why?
|
Renal Replacement Therapy | 5 | 2021 | 8 | 0.770 |
Why?
|
Government Programs | 1 | 2020 | 28 | 0.770 |
Why?
|
Quality of Life | 10 | 2023 | 459 | 0.760 |
Why?
|
Hemodialysis, Home | 2 | 2019 | 2 | 0.740 |
Why?
|
Antioxidants | 4 | 2013 | 386 | 0.740 |
Why?
|
Comprehensive Health Care | 1 | 2019 | 8 | 0.730 |
Why?
|
Nephrosclerosis | 5 | 2010 | 5 | 0.730 |
Why?
|
Child | 17 | 2023 | 2875 | 0.730 |
Why?
|
Health Surveys | 8 | 2018 | 358 | 0.730 |
Why?
|
Apoptosis | 4 | 2014 | 1317 | 0.730 |
Why?
|
Coronary Artery Disease | 3 | 2019 | 147 | 0.720 |
Why?
|
Overweight | 3 | 2018 | 233 | 0.720 |
Why?
|
Internet | 4 | 2013 | 204 | 0.710 |
Why?
|
Meditation | 1 | 2019 | 25 | 0.710 |
Why?
|
Myocytes, Smooth Muscle | 2 | 2010 | 84 | 0.700 |
Why?
|
Sex Factors | 14 | 2017 | 859 | 0.690 |
Why?
|
Anemia | 6 | 2023 | 45 | 0.690 |
Why?
|
Coronavirus Infections | 1 | 2020 | 63 | 0.690 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 70 | 0.680 |
Why?
|
Emergency Service, Hospital | 2 | 2019 | 188 | 0.680 |
Why?
|
Health Status | 4 | 2016 | 356 | 0.670 |
Why?
|
Calcium | 10 | 2010 | 445 | 0.660 |
Why?
|
Odds Ratio | 9 | 2020 | 517 | 0.650 |
Why?
|
Metformin | 4 | 2023 | 64 | 0.650 |
Why?
|
Medicaid | 2 | 2017 | 102 | 0.650 |
Why?
|
Triglycerides | 5 | 2012 | 129 | 0.640 |
Why?
|
Spirituality | 3 | 2022 | 43 | 0.640 |
Why?
|
Research Personnel | 5 | 2022 | 133 | 0.640 |
Why?
|
Research Subjects | 3 | 2015 | 31 | 0.640 |
Why?
|
Body Weight | 4 | 2020 | 404 | 0.640 |
Why?
|
Depression | 5 | 2020 | 664 | 0.630 |
Why?
|
Quality of Health Care | 4 | 2013 | 136 | 0.630 |
Why?
|
Phosphorus | 8 | 2022 | 64 | 0.630 |
Why?
|
Cost of Illness | 3 | 2015 | 79 | 0.630 |
Why?
|
Reimbursement Mechanisms | 1 | 2017 | 10 | 0.600 |
Why?
|
Lipid Metabolism | 5 | 2014 | 109 | 0.590 |
Why?
|
Hyperparathyroidism, Secondary | 9 | 2008 | 9 | 0.590 |
Why?
|
Muscle, Skeletal | 4 | 2013 | 257 | 0.590 |
Why?
|
Education | 5 | 2020 | 48 | 0.590 |
Why?
|
California | 10 | 2023 | 436 | 0.590 |
Why?
|
C-Reactive Protein | 4 | 2022 | 147 | 0.580 |
Why?
|
Follow-Up Studies | 16 | 2020 | 964 | 0.570 |
Why?
|
Decision Support Techniques | 1 | 2016 | 48 | 0.570 |
Why?
|
Kidney Function Tests | 6 | 2020 | 30 | 0.560 |
Why?
|
Awareness | 2 | 2011 | 59 | 0.560 |
Why?
|
Prospective Studies | 14 | 2022 | 1353 | 0.560 |
Why?
|
Poverty Areas | 2 | 2013 | 37 | 0.550 |
Why?
|
Emigrants and Immigrants | 1 | 2017 | 125 | 0.550 |
Why?
|
Aging | 3 | 2013 | 639 | 0.550 |
Why?
|
Databases, Factual | 10 | 2020 | 288 | 0.550 |
Why?
|
Clinical Trials as Topic | 6 | 2018 | 195 | 0.540 |
Why?
|
Feeding Behavior | 4 | 2012 | 418 | 0.530 |
Why?
|
Terminal Care | 3 | 2017 | 47 | 0.530 |
Why?
|
Barbering | 2 | 2016 | 12 | 0.520 |
Why?
|
Community Health Services | 14 | 2015 | 175 | 0.520 |
Why?
|
Urea | 2 | 2012 | 42 | 0.520 |
Why?
|
Schools, Medical | 4 | 2016 | 192 | 0.520 |
Why?
|
Community Health Nursing | 1 | 2014 | 15 | 0.510 |
Why?
|
Uremia | 2 | 2012 | 3 | 0.510 |
Why?
|
Myocardial Ischemia | 1 | 2015 | 72 | 0.510 |
Why?
|
Patient Care | 3 | 2022 | 28 | 0.510 |
Why?
|
Prognosis | 11 | 2019 | 707 | 0.510 |
Why?
|
Time Factors | 16 | 2019 | 1681 | 0.510 |
Why?
|
Drug Therapy, Combination | 5 | 2016 | 217 | 0.500 |
Why?
|
Delivery of Health Care | 3 | 2023 | 254 | 0.500 |
Why?
|
Comorbidity | 11 | 2021 | 606 | 0.500 |
Why?
|
Students, Nursing | 1 | 2014 | 31 | 0.490 |
Why?
|
Selenomethionine | 2 | 2011 | 10 | 0.490 |
Why?
|
Diabetic Retinopathy | 2 | 2013 | 65 | 0.490 |
Why?
|
Proteinuria | 8 | 2013 | 48 | 0.480 |
Why?
|
Longitudinal Studies | 10 | 2022 | 841 | 0.470 |
Why?
|
Patient Selection | 7 | 2015 | 154 | 0.470 |
Why?
|
Dietary Fats | 2 | 2011 | 115 | 0.470 |
Why?
|
Calcium Channel Blockers | 5 | 2009 | 56 | 0.470 |
Why?
|
Dietary Supplements | 4 | 2011 | 196 | 0.470 |
Why?
|
Early Detection of Cancer | 1 | 2016 | 292 | 0.470 |
Why?
|
Urban Health Services | 1 | 2013 | 35 | 0.460 |
Why?
|
Enterocytes | 1 | 2012 | 4 | 0.460 |
Why?
|
Sarcopenia | 1 | 2013 | 9 | 0.460 |
Why?
|
Nephrotic Syndrome | 1 | 2013 | 9 | 0.460 |
Why?
|
Photography | 1 | 2013 | 46 | 0.460 |
Why?
|
Spermine | 2 | 2010 | 64 | 0.450 |
Why?
|
Trust | 4 | 2021 | 119 | 0.450 |
Why?
|
Urease | 1 | 2012 | 15 | 0.450 |
Why?
|
Diagnostic Imaging | 1 | 2013 | 53 | 0.450 |
Why?
|
Length of Stay | 3 | 2020 | 184 | 0.450 |
Why?
|
Health Knowledge, Attitudes, Practice | 6 | 2016 | 790 | 0.450 |
Why?
|
Health Policy | 3 | 2017 | 149 | 0.440 |
Why?
|
Hemodialysis Units, Hospital | 3 | 2021 | 4 | 0.440 |
Why?
|
Dyslipidemias | 1 | 2013 | 42 | 0.440 |
Why?
|
Heart Rate | 3 | 2018 | 248 | 0.440 |
Why?
|
Glutathione | 2 | 2010 | 160 | 0.440 |
Why?
|
Mesenchymal Stem Cells | 2 | 2010 | 54 | 0.440 |
Why?
|
Mexican Americans | 3 | 2012 | 177 | 0.430 |
Why?
|
Prostatic Neoplasms | 2 | 2021 | 794 | 0.430 |
Why?
|
Guidelines as Topic | 3 | 2021 | 50 | 0.420 |
Why?
|
Hyperlipoproteinemia Type I | 1 | 2011 | 1 | 0.420 |
Why?
|
Lipoproteins, VLDL | 1 | 2011 | 3 | 0.420 |
Why?
|
Receptors, Lipoprotein | 1 | 2011 | 3 | 0.420 |
Why?
|
Cell Differentiation | 5 | 2015 | 562 | 0.420 |
Why?
|
Immune System | 1 | 2012 | 40 | 0.420 |
Why?
|
Health Behavior | 3 | 2012 | 491 | 0.420 |
Why?
|
Endothelial Cells | 2 | 2011 | 296 | 0.410 |
Why?
|
Hyperparathyroidism | 2 | 2010 | 5 | 0.410 |
Why?
|
Multivariate Analysis | 10 | 2017 | 570 | 0.410 |
Why?
|
Life Style | 6 | 2023 | 288 | 0.410 |
Why?
|
Patient Discharge | 3 | 2022 | 92 | 0.400 |
Why?
|
Health Personnel | 4 | 2020 | 200 | 0.400 |
Why?
|
Ethics Committees, Research | 1 | 2011 | 9 | 0.400 |
Why?
|
Free Radical Scavengers | 1 | 2011 | 65 | 0.390 |
Why?
|
Interinstitutional Relations | 2 | 2008 | 35 | 0.390 |
Why?
|
Minerals | 2 | 2010 | 45 | 0.390 |
Why?
|
Prejudice | 2 | 2009 | 101 | 0.390 |
Why?
|
Cultural Characteristics | 2 | 2013 | 119 | 0.390 |
Why?
|
Fatty Liver | 1 | 2011 | 56 | 0.380 |
Why?
|
Leadership | 2 | 2021 | 63 | 0.380 |
Why?
|
Foundations | 8 | 2010 | 10 | 0.370 |
Why?
|
Metaphor | 1 | 2010 | 2 | 0.370 |
Why?
|
Mississippi | 5 | 2020 | 107 | 0.370 |
Why?
|
Educational Status | 6 | 2020 | 295 | 0.370 |
Why?
|
Animals | 27 | 2015 | 14307 | 0.370 |
Why?
|
Infant | 7 | 2020 | 1014 | 0.370 |
Why?
|
Cell Shape | 1 | 2010 | 35 | 0.370 |
Why?
|
Data Collection | 3 | 2008 | 188 | 0.370 |
Why?
|
Telemedicine | 1 | 2013 | 163 | 0.370 |
Why?
|
Algorithms | 5 | 2017 | 435 | 0.360 |
Why?
|
Pilot Projects | 10 | 2021 | 628 | 0.360 |
Why?
|
Anemia, Sickle Cell | 2 | 2012 | 169 | 0.360 |
Why?
|
Predictive Value of Tests | 6 | 2021 | 424 | 0.360 |
Why?
|
Urban Population | 6 | 2016 | 318 | 0.350 |
Why?
|
Cardiovascular System | 1 | 2009 | 30 | 0.350 |
Why?
|
Lipoproteins, HDL | 2 | 2013 | 43 | 0.350 |
Why?
|
Social Justice | 3 | 2022 | 53 | 0.340 |
Why?
|
Survival Rate | 8 | 2021 | 310 | 0.340 |
Why?
|
Group Processes | 1 | 2009 | 21 | 0.340 |
Why?
|
Morbidity | 5 | 2017 | 94 | 0.340 |
Why?
|
Signal Transduction | 6 | 2013 | 1802 | 0.340 |
Why?
|
Age Distribution | 4 | 2019 | 223 | 0.340 |
Why?
|
Hospital Mortality | 2 | 2020 | 183 | 0.340 |
Why?
|
Cognitive Science | 1 | 2008 | 3 | 0.330 |
Why?
|
Forecasting | 3 | 2015 | 124 | 0.330 |
Why?
|
Cell Cycle | 1 | 2010 | 309 | 0.330 |
Why?
|
Nutritional Status | 4 | 2021 | 114 | 0.330 |
Why?
|
International Agencies | 1 | 2008 | 5 | 0.330 |
Why?
|
Fibrosis | 1 | 2008 | 146 | 0.320 |
Why?
|
Health Planning | 1 | 2008 | 16 | 0.320 |
Why?
|
Diabetes Complications | 5 | 2014 | 91 | 0.320 |
Why?
|
Diffusion of Innovation | 1 | 2008 | 34 | 0.320 |
Why?
|
Aluminum | 8 | 1989 | 34 | 0.320 |
Why?
|
Collagen | 1 | 2008 | 162 | 0.320 |
Why?
|
Insurance Coverage | 2 | 2008 | 99 | 0.310 |
Why?
|
Serum Albumin | 4 | 2020 | 49 | 0.300 |
Why?
|
Databases as Topic | 1 | 2007 | 18 | 0.300 |
Why?
|
Health Services for the Aged | 1 | 2007 | 17 | 0.300 |
Why?
|
Hypoglycemia | 1 | 2007 | 17 | 0.300 |
Why?
|
Child, Preschool | 7 | 2019 | 1318 | 0.300 |
Why?
|
Patient Compliance | 3 | 2004 | 202 | 0.290 |
Why?
|
Minority Health | 2 | 2019 | 81 | 0.280 |
Why?
|
Adrenergic beta-Antagonists | 5 | 2009 | 50 | 0.280 |
Why?
|
Cross-Cultural Comparison | 1 | 2006 | 100 | 0.280 |
Why?
|
Sodium | 2 | 2009 | 101 | 0.280 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 3 | 2022 | 63 | 0.270 |
Why?
|
Population Groups | 2 | 2008 | 56 | 0.270 |
Why?
|
Gene Expression | 1 | 2008 | 639 | 0.270 |
Why?
|
Cell Proliferation | 2 | 2011 | 1149 | 0.260 |
Why?
|
Arteriovenous Shunt, Surgical | 2 | 2021 | 5 | 0.260 |
Why?
|
Hyponatremia | 1 | 2005 | 6 | 0.260 |
Why?
|
Hypernatremia | 1 | 2005 | 10 | 0.260 |
Why?
|
Urban Health | 3 | 2016 | 86 | 0.260 |
Why?
|
Skilled Nursing Facilities | 1 | 2005 | 9 | 0.260 |
Why?
|
Logistic Models | 4 | 2020 | 894 | 0.260 |
Why?
|
Information Services | 1 | 2004 | 14 | 0.260 |
Why?
|
Hip Fractures | 1 | 2005 | 26 | 0.260 |
Why?
|
Endemic Diseases | 1 | 2004 | 22 | 0.250 |
Why?
|
Pastoral Care | 1 | 2004 | 7 | 0.250 |
Why?
|
Academies and Institutes | 2 | 2015 | 35 | 0.250 |
Why?
|
Clergy | 1 | 2004 | 12 | 0.250 |
Why?
|
Attitude to Death | 1 | 2004 | 20 | 0.250 |
Why?
|
Mice | 9 | 2014 | 5668 | 0.250 |
Why?
|
Early Diagnosis | 8 | 2010 | 62 | 0.250 |
Why?
|
Federal Government | 1 | 2024 | 7 | 0.250 |
Why?
|
Severity of Illness Index | 6 | 2010 | 608 | 0.240 |
Why?
|
Women's Health | 1 | 2005 | 135 | 0.240 |
Why?
|
Calcium Metabolism Disorders | 1 | 2003 | 1 | 0.240 |
Why?
|
Acidosis | 1 | 2004 | 49 | 0.240 |
Why?
|
Receptors, Calcitriol | 4 | 2014 | 59 | 0.240 |
Why?
|
Primary Health Care | 3 | 2012 | 283 | 0.240 |
Why?
|
Apolipoproteins | 1 | 2013 | 19 | 0.240 |
Why?
|
Sex Distribution | 3 | 2019 | 212 | 0.240 |
Why?
|
Brain Ischemia | 2 | 2016 | 179 | 0.240 |
Why?
|
Puerto Rico | 2 | 2019 | 1352 | 0.240 |
Why?
|
Peritoneal Dialysis | 6 | 2009 | 8 | 0.230 |
Why?
|
Adipose Tissue, Brown | 2 | 2014 | 39 | 0.230 |
Why?
|
Extreme Heat | 1 | 2023 | 2 | 0.230 |
Why?
|
Disease Models, Animal | 4 | 2013 | 1300 | 0.230 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2023 | 16 | 0.230 |
Why?
|
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2022 | 1 | 0.230 |
Why?
|
Blood Cell Count | 1 | 2012 | 13 | 0.230 |
Why?
|
Myocytes, Cardiac | 2 | 2015 | 165 | 0.230 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2013 | 233 | 0.230 |
Why?
|
Monocytes | 3 | 2012 | 258 | 0.230 |
Why?
|
Income | 3 | 2020 | 135 | 0.220 |
Why?
|
Phosphorus, Dietary | 1 | 2022 | 1 | 0.220 |
Why?
|
Laboratories | 1 | 2012 | 36 | 0.220 |
Why?
|
Systole | 2 | 2012 | 65 | 0.220 |
Why?
|
Survival Analysis | 5 | 2018 | 322 | 0.220 |
Why?
|
Renin-Angiotensin System | 3 | 2013 | 33 | 0.220 |
Why?
|
Organizational Objectives | 2 | 2016 | 30 | 0.220 |
Why?
|
Hematinics | 2 | 2012 | 6 | 0.220 |
Why?
|
Cells, Cultured | 6 | 2014 | 1442 | 0.220 |
Why?
|
Diet, Protein-Restricted | 2 | 2013 | 5 | 0.220 |
Why?
|
bcl-2-Associated X Protein | 3 | 2011 | 72 | 0.220 |
Why?
|
Dementia | 1 | 2023 | 133 | 0.220 |
Why?
|
Diabetes, Gestational | 1 | 2022 | 46 | 0.210 |
Why?
|
Cause of Death | 4 | 2017 | 154 | 0.210 |
Why?
|
Myostatin | 2 | 2013 | 57 | 0.210 |
Why?
|
Developing Countries | 2 | 2021 | 97 | 0.210 |
Why?
|
Qualitative Research | 4 | 2023 | 393 | 0.210 |
Why?
|
China | 2 | 2021 | 178 | 0.210 |
Why?
|
Lipocalins | 1 | 2011 | 6 | 0.210 |
Why?
|
Research Support as Topic | 3 | 2019 | 75 | 0.210 |
Why?
|
Vaccines | 1 | 2022 | 49 | 0.210 |
Why?
|
Pica | 1 | 2001 | 2 | 0.210 |
Why?
|
Intramolecular Oxidoreductases | 1 | 2011 | 9 | 0.210 |
Why?
|
Decision Making | 3 | 2023 | 189 | 0.210 |
Why?
|
Muscle Development | 2 | 2012 | 44 | 0.210 |
Why?
|
Communication Barriers | 2 | 2017 | 53 | 0.210 |
Why?
|
Rats | 11 | 2014 | 3261 | 0.210 |
Why?
|
Lead Poisoning, Nervous System, Childhood | 1 | 2001 | 8 | 0.210 |
Why?
|
Practice Guidelines as Topic | 3 | 2016 | 187 | 0.210 |
Why?
|
Down-Regulation | 3 | 2013 | 420 | 0.210 |
Why?
|
Calcinosis | 3 | 2008 | 56 | 0.200 |
Why?
|
Follistatin | 2 | 2014 | 27 | 0.200 |
Why?
|
Developed Countries | 1 | 2021 | 12 | 0.200 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 2 | 2013 | 73 | 0.200 |
Why?
|
Cachexia | 2 | 2011 | 7 | 0.200 |
Why?
|
Blood Pressure Determination | 2 | 2016 | 53 | 0.200 |
Why?
|
Diuretics | 2 | 2015 | 49 | 0.200 |
Why?
|
Risk Reduction Behavior | 2 | 2013 | 121 | 0.200 |
Why?
|
Sex | 1 | 2001 | 3 | 0.200 |
Why?
|
Ambulatory Care Facilities | 2 | 2013 | 61 | 0.200 |
Why?
|
Awards and Prizes | 2 | 2018 | 27 | 0.200 |
Why?
|
Uncertainty | 2 | 2021 | 25 | 0.200 |
Why?
|
Models, Organizational | 2 | 2018 | 33 | 0.200 |
Why?
|
Dietary Proteins | 3 | 2022 | 30 | 0.200 |
Why?
|
Social Support | 3 | 2013 | 356 | 0.200 |
Why?
|
Cocaine-Related Disorders | 1 | 2001 | 84 | 0.200 |
Why?
|
Double-Blind Method | 4 | 2018 | 269 | 0.190 |
Why?
|
Models, Cardiovascular | 1 | 2021 | 53 | 0.190 |
Why?
|
Fractures, Bone | 1 | 2020 | 51 | 0.190 |
Why?
|
Circadian Rhythm | 2 | 2022 | 212 | 0.190 |
Why?
|
Pain | 3 | 2001 | 249 | 0.190 |
Why?
|
Spleen | 1 | 2011 | 192 | 0.190 |
Why?
|
Medically Uninsured | 2 | 2013 | 49 | 0.190 |
Why?
|
Walking | 1 | 2021 | 64 | 0.190 |
Why?
|
Gene Expression Profiling | 3 | 2014 | 600 | 0.190 |
Why?
|
North America | 1 | 2020 | 60 | 0.190 |
Why?
|
Patient Care Management | 1 | 2019 | 6 | 0.180 |
Why?
|
Baltimore | 2 | 2020 | 47 | 0.180 |
Why?
|
Focus Groups | 5 | 2017 | 307 | 0.180 |
Why?
|
Drug Evaluation | 2 | 1996 | 9 | 0.180 |
Why?
|
Pain Measurement | 1 | 2001 | 161 | 0.180 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2011 | 139 | 0.180 |
Why?
|
Faculty, Medical | 3 | 2016 | 63 | 0.180 |
Why?
|
Single-Blind Method | 1 | 2019 | 50 | 0.180 |
Why?
|
Hyperkalemia | 1 | 2009 | 13 | 0.180 |
Why?
|
Rats, Sprague-Dawley | 7 | 2013 | 1534 | 0.180 |
Why?
|
Pacific Islands | 1 | 2019 | 115 | 0.180 |
Why?
|
Atherosclerosis | 2 | 2011 | 131 | 0.180 |
Why?
|
Diabetic Foot | 1 | 2019 | 6 | 0.180 |
Why?
|
Altitude | 1 | 2019 | 6 | 0.180 |
Why?
|
Nitrogen | 2 | 2013 | 63 | 0.180 |
Why?
|
Energy Intake | 2 | 2010 | 160 | 0.180 |
Why?
|
Inflammation Mediators | 1 | 2020 | 120 | 0.170 |
Why?
|
Patients | 1 | 1999 | 15 | 0.170 |
Why?
|
Pharmaceutical Preparations | 1 | 2020 | 74 | 0.170 |
Why?
|
Academic Medical Centers | 2 | 2016 | 54 | 0.170 |
Why?
|
Bone Diseases | 4 | 1987 | 18 | 0.170 |
Why?
|
Spiritual Therapies | 1 | 2018 | 9 | 0.170 |
Why?
|
New Orleans | 1 | 2018 | 11 | 0.170 |
Why?
|
Echocardiography | 1 | 2019 | 144 | 0.170 |
Why?
|
New York City | 1 | 2019 | 212 | 0.170 |
Why?
|
Suicide | 1 | 2020 | 114 | 0.170 |
Why?
|
Vitamin D-Binding Protein | 1 | 2018 | 3 | 0.170 |
Why?
|
Behavioral Research | 1 | 2019 | 37 | 0.170 |
Why?
|
Cocaine | 1 | 2001 | 219 | 0.170 |
Why?
|
Self Care | 3 | 2005 | 150 | 0.170 |
Why?
|
Nursing Homes | 1 | 2019 | 41 | 0.170 |
Why?
|
HIV Infections | 2 | 2013 | 2207 | 0.170 |
Why?
|
Annual Reports as Topic | 1 | 2018 | 1 | 0.160 |
Why?
|
Blood Glucose | 2 | 2016 | 333 | 0.160 |
Why?
|
Deferoxamine | 5 | 1988 | 19 | 0.160 |
Why?
|
Attitude to Health | 1 | 2001 | 311 | 0.160 |
Why?
|
Social Class | 2 | 2012 | 228 | 0.160 |
Why?
|
Nurses | 2 | 2021 | 44 | 0.160 |
Why?
|
Waist Circumference | 2 | 2021 | 82 | 0.160 |
Why?
|
Ramipril | 3 | 2008 | 4 | 0.150 |
Why?
|
Gene Expression Regulation | 4 | 2011 | 968 | 0.150 |
Why?
|
Patient Preference | 1 | 2017 | 46 | 0.150 |
Why?
|
Community Health Centers | 2 | 2016 | 45 | 0.150 |
Why?
|
Neutrophils | 2 | 2012 | 124 | 0.150 |
Why?
|
Behavior Therapy | 2 | 2013 | 145 | 0.150 |
Why?
|
Models, Theoretical | 2 | 2009 | 210 | 0.150 |
Why?
|
Liver | 3 | 2012 | 447 | 0.150 |
Why?
|
Blotting, Western | 4 | 2013 | 834 | 0.150 |
Why?
|
Ketosis | 1 | 2016 | 2 | 0.150 |
Why?
|
Congresses as Topic | 2 | 2014 | 38 | 0.150 |
Why?
|
Hypophosphatemia | 1 | 1996 | 1 | 0.150 |
Why?
|
Paralysis | 1 | 1996 | 4 | 0.150 |
Why?
|
Thyrotoxicosis | 1 | 1996 | 3 | 0.150 |
Why?
|
Sodium Chloride Symporter Inhibitors | 2 | 2007 | 8 | 0.150 |
Why?
|
Hypokalemia | 1 | 1996 | 11 | 0.150 |
Why?
|
Fluid Therapy | 1 | 2016 | 27 | 0.150 |
Why?
|
Periodicity | 1 | 1996 | 33 | 0.150 |
Why?
|
Physicians, Women | 1 | 2016 | 4 | 0.140 |
Why?
|
Insulin Resistance | 1 | 2018 | 177 | 0.140 |
Why?
|
Psychometrics | 2 | 2020 | 292 | 0.140 |
Why?
|
Amlodipine | 2 | 2009 | 21 | 0.140 |
Why?
|
Arteriovenous Fistula | 1 | 2016 | 14 | 0.140 |
Why?
|
Motivation | 3 | 2021 | 415 | 0.140 |
Why?
|
Career Mobility | 1 | 2016 | 24 | 0.140 |
Why?
|
Environment Design | 1 | 2016 | 24 | 0.140 |
Why?
|
Maternal Health Services | 3 | 2010 | 11 | 0.140 |
Why?
|
Dietetics | 1 | 2016 | 23 | 0.140 |
Why?
|
Authorship | 1 | 2015 | 5 | 0.140 |
Why?
|
Peer Review, Research | 1 | 2015 | 10 | 0.140 |
Why?
|
Education, Professional | 1 | 2015 | 5 | 0.140 |
Why?
|
Public Opinion | 1 | 2015 | 16 | 0.140 |
Why?
|
Energy Metabolism | 2 | 2014 | 160 | 0.140 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2013 | 638 | 0.140 |
Why?
|
Language | 1 | 2017 | 143 | 0.140 |
Why?
|
Writing | 1 | 2015 | 33 | 0.140 |
Why?
|
Patient Care Team | 2 | 2013 | 44 | 0.130 |
Why?
|
Plasminogen Activator Inhibitor 1 | 2 | 2022 | 22 | 0.130 |
Why?
|
History, 20th Century | 1 | 2015 | 110 | 0.130 |
Why?
|
Attitude of Health Personnel | 2 | 2015 | 186 | 0.130 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2014 | 298 | 0.130 |
Why?
|
Societies, Nursing | 1 | 2014 | 1 | 0.130 |
Why?
|
Mice, Knockout | 3 | 2014 | 897 | 0.130 |
Why?
|
England | 1 | 2014 | 12 | 0.130 |
Why?
|
Arteriovenous Anastomosis | 1 | 2014 | 2 | 0.130 |
Why?
|
Capacity Building | 1 | 2015 | 78 | 0.130 |
Why?
|
Cytokines | 1 | 2018 | 569 | 0.130 |
Why?
|
Interdisciplinary Communication | 4 | 2015 | 34 | 0.130 |
Why?
|
Cartoons as Topic | 1 | 2014 | 3 | 0.130 |
Why?
|
Abnormalities, Multiple | 2 | 2008 | 31 | 0.120 |
Why?
|
Ergocalciferols | 3 | 2010 | 6 | 0.120 |
Why?
|
Patient Admission | 1 | 2014 | 40 | 0.120 |
Why?
|
Chromosome Deletion | 2 | 2008 | 52 | 0.120 |
Why?
|
Peritoneal Dialysis, Continuous Ambulatory | 3 | 1990 | 3 | 0.120 |
Why?
|
Altruism | 1 | 2013 | 12 | 0.120 |
Why?
|
Substance-Related Disorders | 1 | 2001 | 685 | 0.120 |
Why?
|
Heart | 1 | 2015 | 178 | 0.120 |
Why?
|
Patient Acceptance of Health Care | 2 | 2022 | 375 | 0.120 |
Why?
|
Analysis of Variance | 3 | 2023 | 528 | 0.120 |
Why?
|
Health Facility Size | 1 | 2013 | 5 | 0.120 |
Why?
|
Risk | 3 | 2011 | 256 | 0.120 |
Why?
|
Demography | 2 | 2013 | 167 | 0.120 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 605 | 0.120 |
Why?
|
Radiology Information Systems | 1 | 2013 | 5 | 0.120 |
Why?
|
Nursing Staff, Hospital | 1 | 2013 | 10 | 0.120 |
Why?
|
Homeostasis | 3 | 2004 | 172 | 0.120 |
Why?
|
Adipocytes | 1 | 2014 | 54 | 0.120 |
Why?
|
Bone Morphogenetic Protein 7 | 2 | 2013 | 6 | 0.120 |
Why?
|
Adipose Tissue | 2 | 2011 | 167 | 0.120 |
Why?
|
Lipoproteins, IDL | 1 | 2013 | 1 | 0.120 |
Why?
|
Nephritis, Interstitial | 1 | 2013 | 7 | 0.120 |
Why?
|
Ethanol | 2 | 2020 | 188 | 0.110 |
Why?
|
Montana | 2 | 2004 | 5 | 0.110 |
Why?
|
Case Management | 1 | 2013 | 21 | 0.110 |
Why?
|
Electric Impedance | 1 | 2012 | 23 | 0.110 |
Why?
|
Database Management Systems | 1 | 2013 | 19 | 0.110 |
Why?
|
Natural Language Processing | 1 | 2013 | 10 | 0.110 |
Why?
|
Data Mining | 1 | 2013 | 21 | 0.110 |
Why?
|
Nutrition Disorders | 1 | 2012 | 12 | 0.110 |
Why?
|
Spheroids, Cellular | 1 | 2013 | 28 | 0.110 |
Why?
|
Tight Junctions | 1 | 2012 | 24 | 0.110 |
Why?
|
Macrophages | 3 | 2012 | 431 | 0.110 |
Why?
|
School Nursing | 1 | 2012 | 7 | 0.110 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2013 | 49 | 0.110 |
Why?
|
Delayed Graft Function | 1 | 2012 | 1 | 0.110 |
Why?
|
User-Computer Interface | 1 | 2013 | 62 | 0.110 |
Why?
|
Lipoproteins, LDL | 1 | 2013 | 61 | 0.110 |
Why?
|
Cultural Competency | 1 | 2013 | 120 | 0.110 |
Why?
|
NF-kappa B | 3 | 2013 | 306 | 0.110 |
Why?
|
Nutritive Value | 1 | 2012 | 28 | 0.110 |
Why?
|
Mammary Glands, Human | 1 | 2013 | 39 | 0.110 |
Why?
|
Graft Rejection | 1 | 2012 | 38 | 0.110 |
Why?
|
Muscle Fibers, Skeletal | 1 | 2012 | 60 | 0.110 |
Why?
|
Glucaric Acid | 1 | 2011 | 1 | 0.110 |
Why?
|
Health Literacy | 1 | 2014 | 100 | 0.110 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2013 | 73 | 0.110 |
Why?
|
Weight Loss | 2 | 2023 | 124 | 0.110 |
Why?
|
Neovascularization, Physiologic | 1 | 2012 | 70 | 0.110 |
Why?
|
Consensus | 3 | 2021 | 41 | 0.100 |
Why?
|
Thrombocytosis | 1 | 2011 | 5 | 0.100 |
Why?
|
Platelet Count | 1 | 2011 | 17 | 0.100 |
Why?
|
Cyclooxygenase 2 | 2 | 2013 | 92 | 0.100 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2012 | 342 | 0.100 |
Why?
|
Mice, Inbred C57BL | 2 | 2014 | 1530 | 0.100 |
Why?
|
Fatty Acids | 1 | 2012 | 118 | 0.100 |
Why?
|
School Health Services | 1 | 2012 | 77 | 0.100 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 2 | 2010 | 37 | 0.100 |
Why?
|
Ferric Compounds | 1 | 2011 | 49 | 0.100 |
Why?
|
T-Lymphocytes | 2 | 2012 | 341 | 0.100 |
Why?
|
Lipogenesis | 1 | 2011 | 18 | 0.100 |
Why?
|
MAP Kinase Kinase 4 | 1 | 2011 | 31 | 0.100 |
Why?
|
Metoprolol | 2 | 2009 | 3 | 0.100 |
Why?
|
Self Efficacy | 1 | 2012 | 173 | 0.100 |
Why?
|
Rural Population | 1 | 2013 | 253 | 0.100 |
Why?
|
Dendritic Cells | 1 | 2012 | 112 | 0.100 |
Why?
|
Organizational Case Studies | 2 | 2008 | 29 | 0.100 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2012 | 59 | 0.100 |
Why?
|
Bone Density | 2 | 2008 | 76 | 0.100 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 93 | 0.100 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2013 | 209 | 0.100 |
Why?
|
B-Lymphocytes | 1 | 2012 | 181 | 0.100 |
Why?
|
Hypocalcemia | 1 | 2010 | 3 | 0.100 |
Why?
|
Hepatocytes | 1 | 2011 | 74 | 0.100 |
Why?
|
Hypercalcemia | 1 | 2010 | 12 | 0.100 |
Why?
|
Lipoproteins | 1 | 2011 | 61 | 0.100 |
Why?
|
Hypercholesterolemia | 2 | 2009 | 36 | 0.100 |
Why?
|
Intracellular Space | 1 | 2010 | 35 | 0.100 |
Why?
|
Bisexuality | 1 | 2013 | 202 | 0.090 |
Why?
|
Apolipoproteins E | 1 | 2011 | 129 | 0.090 |
Why?
|
Genes, cdc | 1 | 2010 | 8 | 0.090 |
Why?
|
Osteomalacia | 3 | 1987 | 3 | 0.090 |
Why?
|
Multipotent Stem Cells | 1 | 2010 | 16 | 0.090 |
Why?
|
Aldehydes | 1 | 2010 | 65 | 0.090 |
Why?
|
Social Change | 1 | 2010 | 17 | 0.090 |
Why?
|
In Situ Nick-End Labeling | 1 | 2010 | 126 | 0.090 |
Why?
|
Endothelium, Vascular | 1 | 2011 | 229 | 0.090 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2009 | 22 | 0.090 |
Why?
|
rhoA GTP-Binding Protein | 1 | 2010 | 30 | 0.090 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2010 | 91 | 0.090 |
Why?
|
GTP Phosphohydrolases | 1 | 2010 | 29 | 0.090 |
Why?
|
Motor Activity | 1 | 2012 | 393 | 0.090 |
Why?
|
Receptor, Melanocortin, Type 3 | 1 | 2009 | 6 | 0.090 |
Why?
|
gamma-MSH | 1 | 2009 | 4 | 0.090 |
Why?
|
Pregnancy | 3 | 2022 | 1503 | 0.090 |
Why?
|
Intestinal Absorption | 3 | 2003 | 19 | 0.090 |
Why?
|
Models, Educational | 1 | 2009 | 41 | 0.090 |
Why?
|
Blood Platelets | 1 | 1990 | 74 | 0.090 |
Why?
|
Cell Line, Tumor | 2 | 2013 | 2128 | 0.090 |
Why?
|
Health Care Reform | 1 | 2009 | 31 | 0.090 |
Why?
|
Ownership | 1 | 2009 | 10 | 0.090 |
Why?
|
Statistics as Topic | 2 | 2013 | 111 | 0.090 |
Why?
|
Infant, Newborn | 3 | 2016 | 871 | 0.090 |
Why?
|
G-Protein-Coupled Receptor Kinase 4 | 1 | 2009 | 1 | 0.090 |
Why?
|
Hemoglobins | 3 | 2019 | 101 | 0.090 |
Why?
|
Matrix Metalloproteinase 8 | 1 | 2008 | 5 | 0.090 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2010 | 127 | 0.090 |
Why?
|
Catheterization | 2 | 1995 | 23 | 0.090 |
Why?
|
Human Experimentation | 2 | 2008 | 12 | 0.090 |
Why?
|
Enzyme Activation | 1 | 2010 | 423 | 0.090 |
Why?
|
Nutrition Policy | 1 | 2009 | 70 | 0.090 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2008 | 6 | 0.090 |
Why?
|
Mice, Inbred C3H | 1 | 2008 | 83 | 0.090 |
Why?
|
Chromosome Breakage | 1 | 2008 | 14 | 0.080 |
Why?
|
Serpins | 1 | 2008 | 26 | 0.080 |
Why?
|
Biopsy | 3 | 1996 | 151 | 0.080 |
Why?
|
Asthma | 1 | 2013 | 363 | 0.080 |
Why?
|
Nerve Growth Factors | 1 | 2008 | 33 | 0.080 |
Why?
|
Glucose | 1 | 2010 | 217 | 0.080 |
Why?
|
Eye Proteins | 1 | 2008 | 46 | 0.080 |
Why?
|
Chi-Square Distribution | 3 | 2017 | 213 | 0.080 |
Why?
|
Health Care Surveys | 2 | 2008 | 136 | 0.080 |
Why?
|
Education, Medical, Continuing | 2 | 2005 | 31 | 0.080 |
Why?
|
Reproducibility of Results | 2 | 2020 | 901 | 0.080 |
Why?
|
Face | 1 | 2008 | 49 | 0.080 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2008 | 91 | 0.080 |
Why?
|
Polymorphism, Genetic | 1 | 2009 | 165 | 0.080 |
Why?
|
Infant, Low Birth Weight | 1 | 2007 | 37 | 0.080 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2007 | 24 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 2 | 2017 | 528 | 0.080 |
Why?
|
Streptokinase | 1 | 1987 | 2 | 0.080 |
Why?
|
Peritonitis | 1 | 1987 | 8 | 0.080 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2007 | 11 | 0.080 |
Why?
|
Genotype | 4 | 2013 | 641 | 0.080 |
Why?
|
Heart Conduction System | 1 | 2007 | 14 | 0.080 |
Why?
|
Regression Analysis | 2 | 2013 | 429 | 0.080 |
Why?
|
Autonomic Nervous System | 1 | 2007 | 36 | 0.080 |
Why?
|
Sodium Chloride, Dietary | 1 | 2007 | 40 | 0.080 |
Why?
|
Drug Costs | 1 | 2007 | 28 | 0.080 |
Why?
|
Exercise | 2 | 2022 | 524 | 0.080 |
Why?
|
Documentation | 1 | 2007 | 15 | 0.080 |
Why?
|
Medical Records | 1 | 2007 | 37 | 0.080 |
Why?
|
Indians, North American | 2 | 2008 | 145 | 0.070 |
Why?
|
Thrombosis | 1 | 1987 | 61 | 0.070 |
Why?
|
Chemokine CCL2 | 1 | 2007 | 82 | 0.070 |
Why?
|
Electrocardiography | 1 | 2007 | 154 | 0.070 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 555 | 0.070 |
Why?
|
Staphylococcal Infections | 1 | 1987 | 64 | 0.070 |
Why?
|
Reference Values | 1 | 2006 | 204 | 0.070 |
Why?
|
Drug Administration Schedule | 2 | 2003 | 145 | 0.070 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2008 | 214 | 0.070 |
Why?
|
Myocardial Infarction | 1 | 2008 | 221 | 0.070 |
Why?
|
Education, Nursing, Continuing | 2 | 2016 | 11 | 0.070 |
Why?
|
Benzothiadiazines | 1 | 2005 | 3 | 0.070 |
Why?
|
Communication | 1 | 2007 | 170 | 0.070 |
Why?
|
Vasopressins | 1 | 2005 | 12 | 0.070 |
Why?
|
Phosphates | 3 | 2002 | 49 | 0.070 |
Why?
|
Bone Resorption | 2 | 2003 | 7 | 0.070 |
Why?
|
Water-Electrolyte Balance | 1 | 2005 | 17 | 0.070 |
Why?
|
African Americans | 2 | 2001 | 3 | 0.070 |
Why?
|
Patient Advocacy | 1 | 2005 | 20 | 0.070 |
Why?
|
Hypermedia | 1 | 2004 | 1 | 0.070 |
Why?
|
Computer Literacy | 1 | 2004 | 4 | 0.060 |
Why?
|
Adaptation, Psychological | 2 | 2022 | 358 | 0.060 |
Why?
|
Clinical Clerkship | 1 | 2005 | 23 | 0.060 |
Why?
|
Osteoporosis | 1 | 2005 | 32 | 0.060 |
Why?
|
Diabetic Angiopathies | 1 | 2004 | 20 | 0.060 |
Why?
|
Blood Proteins | 1 | 2005 | 65 | 0.060 |
Why?
|
Perception | 1 | 2006 | 183 | 0.060 |
Why?
|
Acid-Base Equilibrium | 1 | 2004 | 7 | 0.060 |
Why?
|
Complementary Therapies | 1 | 2005 | 45 | 0.060 |
Why?
|
Professional-Patient Relations | 1 | 2004 | 44 | 0.060 |
Why?
|
Medically Underserved Area | 1 | 2005 | 98 | 0.060 |
Why?
|
Calcitonin | 1 | 2003 | 5 | 0.060 |
Why?
|
Physician-Patient Relations | 2 | 2004 | 118 | 0.060 |
Why?
|
Organizations | 1 | 2023 | 6 | 0.060 |
Why?
|
Embryo, Mammalian | 2 | 2014 | 152 | 0.060 |
Why?
|
Prescriptions | 1 | 2023 | 17 | 0.060 |
Why?
|
Clinical Competence | 1 | 2004 | 124 | 0.060 |
Why?
|
Maxillofacial Injuries | 1 | 2003 | 2 | 0.060 |
Why?
|
Linear Models | 2 | 2017 | 253 | 0.060 |
Why?
|
Problem Solving | 1 | 2023 | 33 | 0.060 |
Why?
|
Appendectomy | 1 | 2023 | 16 | 0.060 |
Why?
|
Referral and Consultation | 2 | 2015 | 110 | 0.060 |
Why?
|
Hematology | 1 | 2012 | 3 | 0.060 |
Why?
|
Wounds, Gunshot | 1 | 2003 | 26 | 0.060 |
Why?
|
Enalapril | 1 | 2002 | 6 | 0.060 |
Why?
|
Hospitals | 1 | 2023 | 86 | 0.060 |
Why?
|
Hydroxyurea | 1 | 2012 | 34 | 0.060 |
Why?
|
Fibroblast Growth Factors | 1 | 2022 | 34 | 0.050 |
Why?
|
Social Identification | 1 | 2022 | 49 | 0.050 |
Why?
|
Men | 1 | 2022 | 16 | 0.050 |
Why?
|
Syndrome | 1 | 2022 | 72 | 0.050 |
Why?
|
Pharmacists | 1 | 2022 | 53 | 0.050 |
Why?
|
Anticholesteremic Agents | 1 | 2002 | 23 | 0.050 |
Why?
|
AIDS-Associated Nephropathy | 1 | 2002 | 13 | 0.050 |
Why?
|
Lead | 1 | 2003 | 87 | 0.050 |
Why?
|
Lymphocytes | 1 | 2012 | 116 | 0.050 |
Why?
|
Breast Neoplasms | 1 | 2013 | 1426 | 0.050 |
Why?
|
Leisure Activities | 1 | 2022 | 31 | 0.050 |
Why?
|
Micronutrients | 1 | 2022 | 42 | 0.050 |
Why?
|
Fatigue | 1 | 2022 | 79 | 0.050 |
Why?
|
Diagnosis, Differential | 1 | 2002 | 211 | 0.050 |
Why?
|
Hypogonadism | 1 | 2001 | 21 | 0.050 |
Why?
|
Body Composition | 2 | 2013 | 146 | 0.050 |
Why?
|
Erythrocyte Inclusions | 1 | 2011 | 1 | 0.050 |
Why?
|
Erythrocyte Count | 1 | 2011 | 11 | 0.050 |
Why?
|
Sleep | 1 | 2022 | 122 | 0.050 |
Why?
|
Pulse | 1 | 2001 | 10 | 0.050 |
Why?
|
Africa | 1 | 2021 | 62 | 0.050 |
Why?
|
India | 1 | 2021 | 82 | 0.050 |
Why?
|
Mobility Limitation | 1 | 2021 | 12 | 0.050 |
Why?
|
Intensive Care Units | 1 | 2021 | 57 | 0.050 |
Why?
|
Causality | 1 | 2010 | 45 | 0.050 |
Why?
|
Vaccination | 1 | 2022 | 259 | 0.050 |
Why?
|
Up-Regulation | 2 | 2013 | 490 | 0.050 |
Why?
|
Analgesics | 1 | 2001 | 56 | 0.050 |
Why?
|
Religion and Psychology | 1 | 2020 | 25 | 0.050 |
Why?
|
Social Responsibility | 1 | 2020 | 12 | 0.050 |
Why?
|
Professional Competence | 1 | 2020 | 34 | 0.050 |
Why?
|
Employment | 2 | 2011 | 73 | 0.050 |
Why?
|
Testosterone | 1 | 2001 | 181 | 0.050 |
Why?
|
Bone and Bones | 4 | 1991 | 89 | 0.050 |
Why?
|
Software | 1 | 2021 | 204 | 0.050 |
Why?
|
Urinalysis | 1 | 2019 | 31 | 0.040 |
Why?
|
Potassium | 1 | 2009 | 110 | 0.040 |
Why?
|
Health Expenditures | 1 | 2019 | 30 | 0.040 |
Why?
|
Rats, Inbred Dahl | 2 | 2009 | 30 | 0.040 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 1998 | 7 | 0.040 |
Why?
|
Schools | 1 | 2020 | 229 | 0.040 |
Why?
|
Transcription Factors | 2 | 2013 | 653 | 0.040 |
Why?
|
Osteitis Fibrosa Cystica | 2 | 1989 | 2 | 0.040 |
Why?
|
Tracheostomy | 1 | 2017 | 5 | 0.040 |
Why?
|
Intubation, Gastrointestinal | 1 | 2017 | 5 | 0.040 |
Why?
|
Gastrostomy | 1 | 2017 | 7 | 0.040 |
Why?
|
Heredity | 1 | 2017 | 5 | 0.040 |
Why?
|
Personal Autonomy | 1 | 2017 | 17 | 0.040 |
Why?
|
DNA-Binding Proteins | 2 | 2013 | 522 | 0.040 |
Why?
|
Haplotypes | 2 | 2009 | 152 | 0.040 |
Why?
|
Respiration, Artificial | 1 | 2017 | 37 | 0.040 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2017 | 27 | 0.040 |
Why?
|
Least-Squares Analysis | 1 | 2017 | 42 | 0.040 |
Why?
|
Advance Care Planning | 1 | 2017 | 19 | 0.040 |
Why?
|
Family Relations | 1 | 2017 | 45 | 0.040 |
Why?
|
Propensity Score | 1 | 2017 | 40 | 0.040 |
Why?
|
Censuses | 1 | 2017 | 24 | 0.040 |
Why?
|
Antithyroid Agents | 1 | 1996 | 1 | 0.040 |
Why?
|
Graves Disease | 1 | 1996 | 3 | 0.040 |
Why?
|
Propylthiouracil | 1 | 1996 | 3 | 0.040 |
Why?
|
Disease Management | 1 | 2017 | 61 | 0.040 |
Why?
|
Potassium Chloride | 1 | 1996 | 25 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 1996 | 48 | 0.040 |
Why?
|
Interviews as Topic | 1 | 2017 | 356 | 0.040 |
Why?
|
Muscular Diseases | 2 | 1986 | 20 | 0.040 |
Why?
|
Frail Elderly | 1 | 2016 | 15 | 0.040 |
Why?
|
Acute Disease | 1 | 1996 | 141 | 0.040 |
Why?
|
Faculty, Dental | 1 | 2015 | 2 | 0.030 |
Why?
|
Culture | 1 | 1997 | 162 | 0.030 |
Why?
|
Marketing of Health Services | 1 | 2015 | 7 | 0.030 |
Why?
|
Meningitis, Bacterial | 1 | 1995 | 8 | 0.030 |
Why?
|
Streptococcus agalactiae | 1 | 1995 | 10 | 0.030 |
Why?
|
Choroid | 1 | 1995 | 10 | 0.030 |
Why?
|
Retinal Vessels | 1 | 1995 | 24 | 0.030 |
Why?
|
Atrial Fibrillation | 1 | 2016 | 105 | 0.030 |
Why?
|
Streptococcal Infections | 1 | 1995 | 32 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2017 | 1056 | 0.030 |
Why?
|
Karyotyping | 2 | 2008 | 46 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2008 | 49 | 0.030 |
Why?
|
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone | 1 | 2014 | 6 | 0.030 |
Why?
|
Access to Information | 1 | 2014 | 13 | 0.030 |
Why?
|
Video Recording | 1 | 2014 | 32 | 0.030 |
Why?
|
Chromosome Mapping | 2 | 2008 | 159 | 0.030 |
Why?
|
Thermogenesis | 1 | 2014 | 20 | 0.030 |
Why?
|
Cold Temperature | 1 | 2014 | 39 | 0.030 |
Why?
|
Oxygen Consumption | 1 | 2014 | 98 | 0.030 |
Why?
|
Immunoblotting | 1 | 2014 | 170 | 0.030 |
Why?
|
Poisson Distribution | 1 | 2013 | 39 | 0.030 |
Why?
|
Curriculum | 1 | 2015 | 237 | 0.030 |
Why?
|
Protein Transport | 1 | 2014 | 286 | 0.030 |
Why?
|
Arachidonate 12-Lipoxygenase | 1 | 2013 | 3 | 0.030 |
Why?
|
Boston | 1 | 2013 | 20 | 0.030 |
Why?
|
Glutamate-Cysteine Ligase | 1 | 2013 | 17 | 0.030 |
Why?
|
Heme Oxygenase-1 | 1 | 2013 | 46 | 0.030 |
Why?
|
Ion Channels | 1 | 2013 | 69 | 0.030 |
Why?
|
Retinoid X Receptors | 1 | 2013 | 11 | 0.030 |
Why?
|
Adenine | 1 | 2013 | 43 | 0.030 |
Why?
|
Diacylglycerol O-Acyltransferase | 1 | 2012 | 1 | 0.030 |
Why?
|
Fibroblast Growth Factor 1 | 1 | 2012 | 4 | 0.030 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2012 | 16 | 0.030 |
Why?
|
Tissue Inhibitor of Metalloproteinase-3 | 1 | 2012 | 9 | 0.030 |
Why?
|
Erythropoiesis | 1 | 2012 | 13 | 0.030 |
Why?
|
Catalase | 1 | 2013 | 106 | 0.030 |
Why?
|
Cell Separation | 1 | 2013 | 91 | 0.030 |
Why?
|
Gene Regulatory Networks | 1 | 2013 | 115 | 0.030 |
Why?
|
Mitochondrial Proteins | 1 | 2013 | 96 | 0.030 |
Why?
|
Cell Nucleus | 1 | 2014 | 351 | 0.030 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2012 | 41 | 0.030 |
Why?
|
Pediatrics | 1 | 2013 | 66 | 0.030 |
Why?
|
Graft Survival | 1 | 2012 | 34 | 0.030 |
Why?
|
PPAR gamma | 1 | 2012 | 49 | 0.030 |
Why?
|
Neoplastic Stem Cells | 1 | 2013 | 74 | 0.030 |
Why?
|
Fibroblasts | 1 | 2014 | 252 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2013 | 142 | 0.030 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2013 | 89 | 0.030 |
Why?
|
Aorta, Thoracic | 1 | 2011 | 24 | 0.030 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2013 | 242 | 0.030 |
Why?
|
Diastole | 1 | 2012 | 46 | 0.030 |
Why?
|
Mice, Nude | 1 | 2013 | 323 | 0.030 |
Why?
|
Health Services Needs and Demand | 1 | 2013 | 143 | 0.030 |
Why?
|
Food Preferences | 1 | 2012 | 66 | 0.030 |
Why?
|
Dialysis | 1 | 2011 | 6 | 0.030 |
Why?
|
Albumins | 1 | 2011 | 24 | 0.030 |
Why?
|
MyoD Protein | 1 | 2011 | 9 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2012 | 157 | 0.030 |
Why?
|
Diagnosis-Related Groups | 1 | 2011 | 12 | 0.030 |
Why?
|
Growth Differentiation Factors | 1 | 2011 | 7 | 0.030 |
Why?
|
Vasodilation | 1 | 2011 | 65 | 0.030 |
Why?
|
Erythropoietin | 1 | 2011 | 37 | 0.030 |
Why?
|
Bone Morphogenetic Proteins | 1 | 2011 | 22 | 0.030 |
Why?
|
Insulin-Like Growth Factor II | 1 | 2011 | 22 | 0.030 |
Why?
|
Risk Adjustment | 1 | 2011 | 17 | 0.030 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2011 | 54 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2013 | 178 | 0.020 |
Why?
|
Israel | 1 | 2010 | 18 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2011 | 209 | 0.020 |
Why?
|
Thiobarbituric Acid Reactive Substances | 1 | 2010 | 15 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 2010 | 51 | 0.020 |
Why?
|
Bone Density Conservation Agents | 1 | 2010 | 22 | 0.020 |
Why?
|
Nitric Oxide | 1 | 2013 | 287 | 0.020 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2012 | 283 | 0.020 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2010 | 63 | 0.020 |
Why?
|
Nitric Oxide Synthase Type I | 1 | 2010 | 51 | 0.020 |
Why?
|
Adiponectin | 1 | 2010 | 52 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2010 | 97 | 0.020 |
Why?
|
Interleukin-6 | 1 | 2011 | 140 | 0.020 |
Why?
|
Carbon-Carbon Ligases | 1 | 2009 | 1 | 0.020 |
Why?
|
Scavenger Receptors, Class E | 1 | 2009 | 4 | 0.020 |
Why?
|
Hydroxymethylglutaryl CoA Reductases | 1 | 2009 | 4 | 0.020 |
Why?
|
Sterol Regulatory Element Binding Protein 2 | 1 | 2009 | 5 | 0.020 |
Why?
|
Sterol Regulatory Element Binding Protein 1 | 1 | 2009 | 9 | 0.020 |
Why?
|
Cytosol | 1 | 1990 | 85 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 94 | 0.020 |
Why?
|
Drug Prescriptions | 1 | 2010 | 42 | 0.020 |
Why?
|
Caspase 3 | 1 | 2010 | 194 | 0.020 |
Why?
|
Antidepressive Agents | 1 | 2010 | 53 | 0.020 |
Why?
|
Sucralfate | 1 | 1989 | 2 | 0.020 |
Why?
|
Personal Satisfaction | 1 | 2010 | 56 | 0.020 |
Why?
|
Telemetry | 1 | 2009 | 14 | 0.020 |
Why?
|
Radioimmunoassay | 1 | 2009 | 66 | 0.020 |
Why?
|
Sodium, Dietary | 1 | 2009 | 25 | 0.020 |
Why?
|
Receptors, Scavenger | 1 | 2009 | 13 | 0.020 |
Why?
|
Parents | 1 | 2012 | 288 | 0.020 |
Why?
|
Anti-Inflammatory Agents | 1 | 2011 | 137 | 0.020 |
Why?
|
Nephrectomy | 1 | 2009 | 23 | 0.020 |
Why?
|
Leptin | 1 | 2010 | 115 | 0.020 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2010 | 243 | 0.020 |
Why?
|
Bone Diseases, Metabolic | 1 | 1988 | 9 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2011 | 325 | 0.020 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2008 | 20 | 0.020 |
Why?
|
Cell Line | 1 | 2012 | 1289 | 0.020 |
Why?
|
Alleles | 1 | 2009 | 284 | 0.020 |
Why?
|
Cell Survival | 1 | 2011 | 818 | 0.020 |
Why?
|
Microcephaly | 1 | 2008 | 18 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2008 | 82 | 0.020 |
Why?
|
Social Environment | 1 | 2010 | 186 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2012 | 1152 | 0.020 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 2007 | 23 | 0.020 |
Why?
|
I-kappa B Proteins | 1 | 2007 | 38 | 0.020 |
Why?
|
Autonomic Nerve Block | 1 | 2007 | 3 | 0.020 |
Why?
|
Developmental Disabilities | 1 | 2008 | 59 | 0.020 |
Why?
|
Atropine | 1 | 2007 | 12 | 0.020 |
Why?
|
Renin | 1 | 2007 | 29 | 0.020 |
Why?
|
Propranolol | 1 | 2007 | 17 | 0.020 |
Why?
|
Long QT Syndrome | 1 | 2007 | 12 | 0.020 |
Why?
|
Body Size | 1 | 2007 | 28 | 0.020 |
Why?
|
Lipids | 1 | 2009 | 222 | 0.020 |
Why?
|
Drug Combinations | 1 | 2007 | 89 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 781 | 0.020 |
Why?
|
Recurrence | 1 | 1987 | 125 | 0.020 |
Why?
|
Calcium Carbonate | 1 | 1987 | 8 | 0.020 |
Why?
|
Sex Characteristics | 1 | 2009 | 213 | 0.020 |
Why?
|
Needles | 1 | 1986 | 8 | 0.020 |
Why?
|
Angiotensin II | 1 | 2007 | 92 | 0.020 |
Why?
|
Carrier Proteins | 1 | 2009 | 287 | 0.020 |
Why?
|
Sulfonamides | 1 | 2007 | 75 | 0.020 |
Why?
|
Hematologic Diseases | 1 | 1986 | 14 | 0.020 |
Why?
|
Administration, Oral | 2 | 2001 | 212 | 0.020 |
Why?
|
Public Health Informatics | 1 | 2006 | 8 | 0.020 |
Why?
|
Alkaline Phosphatase | 2 | 2000 | 48 | 0.020 |
Why?
|
Diet | 1 | 2012 | 747 | 0.020 |
Why?
|
Fractures, Spontaneous | 1 | 1985 | 6 | 0.020 |
Why?
|
Phenotype | 1 | 2008 | 650 | 0.020 |
Why?
|
Injections, Intravenous | 2 | 2001 | 58 | 0.020 |
Why?
|
DNA | 1 | 2009 | 549 | 0.020 |
Why?
|
Models, Biological | 1 | 2009 | 642 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2009 | 486 | 0.020 |
Why?
|
Competency-Based Education | 1 | 2005 | 9 | 0.020 |
Why?
|
Specialization | 1 | 2005 | 21 | 0.020 |
Why?
|
Violence | 1 | 2006 | 126 | 0.020 |
Why?
|
Phosphorylation | 1 | 2007 | 878 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2007 | 984 | 0.020 |
Why?
|
Metabolic Diseases | 1 | 2004 | 32 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2004 | 53 | 0.020 |
Why?
|
Calcaneus | 1 | 2003 | 2 | 0.010 |
Why?
|
Skull Fractures | 1 | 2003 | 4 | 0.010 |
Why?
|
Spectrometry, X-Ray Emission | 1 | 2003 | 17 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2004 | 206 | 0.010 |
Why?
|
Pharynx | 1 | 2003 | 12 | 0.010 |
Why?
|
Foreign Bodies | 1 | 2003 | 6 | 0.010 |
Why?
|
Nose | 1 | 2003 | 14 | 0.010 |
Why?
|
Facial Bones | 1 | 2003 | 13 | 0.010 |
Why?
|
Tibia | 1 | 2003 | 18 | 0.010 |
Why?
|
Radiography | 1 | 2003 | 75 | 0.010 |
Why?
|
Students, Medical | 1 | 2005 | 121 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2003 | 151 | 0.010 |
Why?
|
Mouth | 1 | 2003 | 44 | 0.010 |
Why?
|
Patient-Centered Care | 1 | 2003 | 51 | 0.010 |
Why?
|
Occupational Exposure | 1 | 2003 | 67 | 0.010 |
Why?
|
Needs Assessment | 1 | 2003 | 159 | 0.010 |
Why?
|
Half-Life | 1 | 2001 | 52 | 0.010 |
Why?
|
Administration, Cutaneous | 1 | 2001 | 38 | 0.010 |
Why?
|
Drug Administration Routes | 1 | 2001 | 12 | 0.010 |
Why?
|
Hormones | 1 | 2001 | 51 | 0.010 |
Why?
|
Environmental Exposure | 1 | 2003 | 207 | 0.010 |
Why?
|
Arteriosclerosis | 1 | 2001 | 35 | 0.010 |
Why?
|
Carotid Artery Diseases | 1 | 2001 | 22 | 0.010 |
Why?
|
Smoking | 1 | 2007 | 903 | 0.010 |
Why?
|
Biological Availability | 2 | 1990 | 84 | 0.010 |
Why?
|
Kidney Diseases, Cystic | 1 | 1998 | 3 | 0.010 |
Why?
|
Hand Deformities, Congenital | 1 | 1998 | 3 | 0.010 |
Why?
|
Microsatellite Repeats | 1 | 1998 | 51 | 0.010 |
Why?
|
Craniofacial Abnormalities | 1 | 1998 | 21 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 1996 | 30 | 0.010 |
Why?
|
Radioisotope Renography | 1 | 1996 | 11 | 0.010 |
Why?
|
Regional Blood Flow | 1 | 1995 | 47 | 0.010 |
Why?
|
Injections, Intraventricular | 1 | 1995 | 60 | 0.010 |
Why?
|
Hypotension | 1 | 1995 | 21 | 0.010 |
Why?
|
Blood Flow Velocity | 1 | 1995 | 63 | 0.010 |
Why?
|
Microspheres | 1 | 1995 | 45 | 0.010 |
Why?
|
Hemodynamics | 1 | 1995 | 86 | 0.010 |
Why?
|
Random Allocation | 1 | 1995 | 139 | 0.010 |
Why?
|
Swine | 1 | 1995 | 182 | 0.010 |
Why?
|
Animals, Newborn | 1 | 1995 | 323 | 0.010 |
Why?
|
Parathyroid Glands | 1 | 1991 | 5 | 0.010 |
Why?
|
Injections | 1 | 1991 | 35 | 0.010 |
Why?
|
Magnesium | 1 | 1991 | 95 | 0.010 |
Why?
|
Infusions, Parenteral | 1 | 1989 | 12 | 0.010 |
Why?
|
Aluminum Hydroxide | 1 | 1989 | 7 | 0.010 |
Why?
|
Osteoblasts | 1 | 1989 | 33 | 0.010 |
Why?
|
Brain Diseases | 1 | 1988 | 33 | 0.010 |
Why?
|
Bone Development | 1 | 1987 | 15 | 0.010 |
Why?
|
Brain | 1 | 1995 | 1268 | 0.000 |
Why?
|
Gels | 1 | 1987 | 41 | 0.000 |
Why?
|
Injections, Intraperitoneal | 1 | 1986 | 58 | 0.000 |
Why?
|
Complement System Proteins | 1 | 1986 | 21 | 0.000 |
Why?
|
Parenteral Nutrition, Total | 1 | 1986 | 2 | 0.000 |
Why?
|
Microscopy, Fluorescence | 1 | 1986 | 240 | 0.000 |
Why?
|